Keywords: strong, ph, iii, head-line, data, actemra, swiss

Strong Ph III head-line data for Actemra

Article | 29 January 2007

Print This

Swiss drug major Roche says that the first multinational Phase III study of Actemra (tocilizumab) outside Japan, met its primary ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in